Richard C Strange
Overview
Explore the profile of Richard C Strange including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
2069
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hackett G, Mann A, Haider A, Haider K, Desnerck P, Konig C, et al.
World J Mens Health
. 2024 Mar;
42(4):749-761.
PMID: 38449452
Purpose: While testosterone therapy can improve the various pathologies associated with adult-onset testosterone deficiency (TD), Summary of Product Characteristics (SPC) of five testosterone preparations caution that treatment may be associated...
2.
Mann A, Strange R, Konig C, Hackett G, Haider A, Haider K, et al.
Andrology
. 2023 Dec;
12(6):1389-1397.
PMID: 38148671
Objectives: We describe studies determining the association between testosterone therapy (TTh) and mortality. Materials & Methods: We used a registry database of 737 men with adult-onset testosterone deficiency defined as...
3.
Ramachandran S, Hackett G, Strange R
Andrology
. 2020 May;
8(5):1222-1232.
PMID: 32384175
Background: Testosterone replacement therapy (TRT) improves health in some but not all men with type 2 diabetes (T2DM) and adult-onset testosterone deficiency (TD). Such heterogeneity is compatible with the concept...
4.
Ramachandran S, Hackett G, Strange R
Sex Med Rev
. 2019 Aug;
7(4):669-678.
PMID: 31447413
Introduction: The age-related fall in male testosterone levels can have clinical consequences. The concentration of serum-free testosterone, the putative bioactive moiety, is mediated by carrier proteins, especially SHBG. Aim: The...
5.
Konig C, Balabani S, Hackett G, Strange R, Ramachandran S
Sex Med Rev
. 2019 Mar;
7(4):650-660.
PMID: 30926458
Introduction: Clinical guidelines indicate that hematocrit should be monitored during testosterone replacement therapy (TTh), with action taken if a level of 0.54 is exceeded. Aim: To consider the extent of...
6.
Hackett G, Cole N, Mulay A, Strange R, Ramachandran S
BJU Int
. 2018 Sep;
123(3):519-529.
PMID: 30216622
Objectives: To further characterize the beneficial impact of testosterone replacement therapy (TRT) on the association between mortality and hypogonadism (HG) in men with type 2 diabetes (T2DM), by determining, firstly,...
7.
Hackett G, Cole N, Mulay A, Strange R, Ramachandran S
World J Mens Health
. 2018 Sep;
38(1):68-77.
PMID: 30209900
Purpose: To describe the 4-year metabolic follow-up results from the BLAST study. Materials And Methods: Baseline hemoglobin A1c (HbA1c), weight, and waist circumference (WC) data were recorded in 185 men...
8.
Hackett G, Jones P, Strange R, Ramachandran S
World J Diabetes
. 2017 Mar;
8(3):104-111.
PMID: 28344753
Aim: To determine how statins, testosterone (T) replacement therapy (TRT) and phosphodiesterase 5-inhibitors (PDE5I) influence age related mortality in diabetic men. Methods: We studied 857 diabetic men screened for the...
9.
Groves C, Shetty C, Strange R, Waldron J, Ramachandran S
Postgrad Med J
. 2016 Aug;
93(1098):205-208.
PMID: 27531965
Purpose Of The Study: Statins and ezetimibe reduce low-density lipoprotein cholesterol (LDL-c) and cardiovascular disease (CVD) risk. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors lower LDL-c by 50%-70% and might...
10.
Shipman K, Strange R, Ramachandran S
World J Diabetes
. 2016 Mar;
7(5):74-88.
PMID: 26981181
The use of fibrates in the treatment of dyslipidaemia has changed significantly over recent years. Their role appeared clear at the start of this century. The Helsinki Heart Study and...